The role of bevacizumab in the treatment of glioblastoma

  title={The role of bevacizumab in the treatment of glioblastoma},
  author={R. Diaz and Sheikh C. Ali and Mehreen Gull Qadir and M. D. L. Fuente and M. Ivan and R. Komotar},
  journal={Journal of Neuro-Oncology},
  • R. Diaz, Sheikh C. Ali, +3 authors R. Komotar
  • Published 2017
  • Medicine
  • Journal of Neuro-Oncology
  • Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited… CONTINUE READING
    71 Citations
    Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
    • 9
    • PDF
    A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma
    • 4
    Bevacizumab: Is the lower the better for glioblastoma patients in progression?
    • 1
    • Highly Influenced
    • PDF
    Therapeutic Immunization against Glioblastoma
    • 7
    • PDF


    Bevacizumab and chemotherapy for recurrent glioblastoma
    • 211
    • PDF
    Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
    • 26
    • PDF
    A randomized trial of bevacizumab for newly diagnosed glioblastoma.
    • 1,563
    • Highly Influential
    • PDF
    A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    • 114
    • PDF
    Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    • 1,970
    • Highly Influential
    • PDF